Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers
about
Antagonizing programmed death-1 and programmed death ligand-1 as a therapeutic approach for gastric cancerClinicopathologic implications of immune classification by PD-L1 expression and CD8-positive tumor-infiltrating lymphocytes in stage II and III gastric cancer patients.Molecular classifications of gastric cancers: Novel insights and possible future applications.Inhibitors of the PD-1/PD-L1 axis for the treatment of head and neck cancer: current status and future perspectivesThe PD-1, PD-L1 expression and CD3+ T cell infiltration in relation to outcome in advanced gastric signet-ring cell carcinoma, representing a potential biomarker for immunotherapy.PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma.Gastric Cancer Genomics: Advances and Future Directions.Receptor tyrosine kinase amplified gastric cancer: Clinicopathologic characteristics and proposed screening algorithmProgrammed cell death-ligand 1 expression predicts survival in patients with gastric carcinoma with microsatellite instability.PD-L1 and gastric cancer prognosis: A systematic review and meta-analysis.PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy.Clinical application of early gastric carcinoma with lymphoid stroma based on lymph node metastasis status.Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway.Novel Targeted Therapies for Esophagogastric Cancer.The Role of Epigenetic Regulation in Epstein-Barr Virus-Associated Gastric Cancer.Immunotherapeutic Strategies for Gastric Carcinoma: A Review of Preclinical and Clinical Recent Development.Combined prognostic effect of PD-L1 expression and immunoscore in microsatellite-unstable advanced gastric cancers.Intratumoural PD-L1 expression is associated with worse survival of patients with Epstein-Barr virus-associated gastric cancer.The perivascular microenvironment in Epstein-Barr virus positive primary central nervous system lymphoma: The role of programmed cell death 1 and programmed cell death ligand 1.Tumor-infiltrating CD4+ T cells in patients with gastric cancer.Programmed death ligand-1 and MET co-expression is a poor prognostic factor in gastric cancers after resection.IFNγ induces PD-L1 overexpression by JAK2/STAT1/IRF-1 signaling in EBV-positive gastric carcinoma.Modulation of the Tumor Microenvironment by Epstein-Barr virus Latent Membrane Protein-1 in Nasopharyngeal Carcinoma.Immune Activation and Benefit From Avelumab in EBV-Positive Gastric Cancer.Elevated Levels of Interferon-γ Are Associated with High Levels of Epstein-Barr Virus Reactivation in Patients with the Intestinal Type of Gastric Cancer.Host immune response index in gastric cancer identified by comprehensive analyses of tumor immunity.Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma.Characterization and validation of potential therapeutic targets based on the molecular signature of patient-derived xenografts in gastric cancer.Gastric cancer: Basic aspects.Novel Systemic Therapies for Advanced Gastric Cancer.Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas.Current status of immunotherapy and immune biomarkers in gastro-esophageal cancers.Modulation of Gut Microbiota: A Novel Paradigm of Enhancing the Efficacy of Programmed Death-1 and Programmed Death Ligand-1 Blockade Therapy.Analysis of PD1, PDL1, PDL2 expression and T cells infiltration in 1014 gastric cancer patients.Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial.The Microenvironment in Epstein-Barr Virus-Associated Malignancies.Four distinct immune microenvironment subtypes in gastric adenocarcinoma with special reference to microsatellite instability.EBV⁺ and MSI Gastric Cancers Harbor High PD-L1/PD-1 Expression and High CD8⁺ Intratumoral Lymphocytes.Single agent anti PD-1 inhibitors in esophageal cancer-a first step in a new therapeutic direction.Advances in immuno-oncology biomarkers for gastroesophageal cancer: Programmed death ligand 1, microsatellite instability, and beyond.
P2860
Q28066532-F95EEE05-EB24-4762-8DCF-7544B38D542FQ33688662-C7480387-0C7A-4A14-A1A6-7B0EB25D7C8FQ33696201-80EF158D-0C8D-44D3-87D2-D4D21377F7F2Q33884361-E8A8FEC7-AA81-4C7E-98F4-A2C02D6AB518Q33888982-6B987E55-9068-4533-A311-1C2D681E02D9Q37340738-D7E64C48-A1EF-4268-A1C2-2A170A10EB7BQ37673604-4BCF9A9A-064D-4C06-8D31-7C55766EA370Q37687784-66DCB4E8-362B-4CE4-A3FB-1FFD92168AB1Q37706604-5C2B2E92-DA96-4864-91A6-E53383A9F0CCQ38630412-50177008-1619-4B81-A518-A728CA0B6B99Q38642853-BF7319A7-B9E8-4ED0-873B-90E4079AC815Q38958539-A3E828FE-D702-4C7A-AD7B-2907DDD7EB89Q38996832-12EF5D86-C2BE-43F5-860C-B6B732654FE1Q39171565-F9304BA4-03DC-4A09-B067-9583D52694CFQ40102087-49546B1E-D866-4447-A7A6-EB5939AF1A9CQ41110505-B2D14573-230A-4EFA-9749-7279C6E0133BQ41708934-5DFCC6F7-383B-44F2-A458-B7030C15E024Q45325629-90719986-E0C9-4AD7-9589-4386D414B8CDQ45325729-22771BA6-17F0-4D36-8FD3-6D5019286810Q47099025-882A4AD5-7DCF-4FD3-8AA1-D1E7AFD8F377Q47143363-C8CAA5EE-E500-4299-AD6E-A3DE87DA2547Q47273046-D30D6459-8526-4DF5-9976-15B84A31C9F7Q47286778-466377B7-FCF4-4B52-90CF-257A22F70706Q47443241-D5FF749C-E4D6-477D-A42E-E5C7726B46FFQ47551595-FAFFEF7B-76C8-4133-A29A-E041AA918DE5Q47577423-6BEAC0E9-0DCB-4D3C-B3B9-7B3A240874FCQ47864236-3DB83E78-C46E-404C-8BA7-AC49F704963EQ50057702-B7504DBC-CCD5-4D44-8022-FC64EC48321CQ50168318-FAC130B3-2D9A-4F77-90D9-86002D7F15B2Q52599496-3884B05D-E1D3-401C-95F6-5A3918178A03Q52603962-A401902E-C688-4C6E-9CA3-92A021118772Q52643527-87555564-EDAF-4070-8A52-960BF044599FQ52647752-D17BA12C-0750-4995-8787-684095AB1BA3Q52733772-17378B0D-14DF-46E5-9C22-45D3EE2B5034Q53837214-6FCFE598-5D6E-4051-95CA-F198AA649ABEQ54236409-D2C7BDD4-3347-4800-94CA-5583D0A23FC0Q54238201-FFBCBA35-51C6-4960-A89B-258EC91B38FBQ55082025-48CB2ABA-9328-4CF9-9AB4-74F21DABD455Q55196621-25C4521A-CCB5-4B94-AE45-95D9A1D9202BQ55506755-EC74E2AF-3860-4365-9D1B-362EFA6E47B4
P2860
Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 28 April 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers
@en
Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers.
@nl
type
label
Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers
@en
Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers.
@nl
prefLabel
Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers
@en
Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers.
@nl
P2093
P2860
P356
P1433
P1476
Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers
@en
P2093
Adam J Bass
Charles S Rabkin
Enrico Solcia
Fausto Sessa
Gordon J Freeman
M Constanza Camargo
Sarah Derks
Scott J Rodig
Tania Fleitas
Xiaoyun Liao
P2860
P304
32925-32932
P356
10.18632/ONCOTARGET.9076
P407
P577
2016-05-01T00:00:00Z